To validate tumor-infiltration and systemic activation of CD8+ T cells, a 89Zr-desferrioxamine-labeled anti-CD8 cys-diabody (89Zr-malDFO-169 cDb) was used for monitoring. Here, CD8A is linked to neoplasm.